Currently, radionuclide imaging after injection of radiolabeled tracers seems to be the most
promising approach to noninvasively determine the beta cell mass (BCM) in vivo. Despite …

Radiotracer imaging is characterised by high in vivo sensitivity, with a detection limit in the
lower picomolar range. Therefore, radiotracers represent a valuable tool for imaging …

Islet transplantation is a promising treatment option for patients with type 1 diabetes (T1D);
however, the fate of the graft over time remains difficult to follow, due to the lack of available …

Background: Currently there are major efforts to develop strategies for the in vivo imaging of
pancreatic beta cell mass as a clinical and investigational tool for detecting and tracking the …

Introduction Advances in positron emission tomography (PET) imaging have provided
opportunities to develop radiotracers specific for imaging insulin-producing pancreatic β …

Diabetes mellitus is a growing worldwide epidemic disease, currently affecting 1 in 12
adults. Treatment of disease complications typically consumes∼ 10% of healthcare budgets …

In this commentary, we describe the limitations of positron emission tomography (PET) in
visualising and characterising beta cell mass in the native pancreas in healthy individuals …

The development of non-invasive imaging methods for early diagnosis of the beta cell
associated metabolic diseases, including type 1 and type 2 diabetes (T1D and T2D), has …

For more than a decade, researchers have been trying to develop non-invasive imaging
techniques for the in vivo measurement of viable pancreatic beta cells. However, in spite of …

We read with interest the review by Arifin and Bulte [1], which concluded that pancreatic β-
cell mass (BCM) imaging remains a daunting task because of a lack of specific β-cell …